Global API Waterstone operates with a global footprint including an API manufacturing facility and R&D center, indicating strong potential for international supply partnerships and cross-border contract manufacturing opportunities with both Western and Asian life sciences customers.

Series C Momentum Recent $61M Series C financing signals strong growth potential and investor confidence, creating a favorable window to pursue strategic alliances, co-development deals, and expanded product lines with the company as it scales.

Product Catalog With a catalog of over 30,000 research products and capabilities in custom synthesis and cGMP APIs, there are ample opportunities to position Waterstone as a one-stop supplier for CROs, CDMOs, and pharma manufacturers seeking diverse starting materials and API sourcing.

Regulatory Readiness The established ICH Q7 and US FDA cGMP compliant facilities suggest reliability for GMP-grade supply, enabling outreach to regulated manufacturers needing compliant materials, large-scale manufacturing, or fast-track API access.

Emerging Market Access Indianapolis base with Wuhan operations indicates capability to serve both North American and Chinese/APAC markets, presenting cross-regional sales opportunities, JV discussions, and regional supply chain partnerships for multinational clients.